title: Limited-angle x-ray luminescence tomography: methodology and feasibility study.
abstract: X-ray luminescence tomography (XLT) has recently been proposed as a new imaging modality for biological imaging applications. This modality utilizes phosphor nanoparticles which luminesce near-infrared light when excited by x-ray photons. The advantages of this modality are that it uniquely combines the high sensitivity of radioluminescent nanoparticles and the high spatial localization of collimated x-ray beams. Currently, XLT has been demonstrated using x-ray spatial encoding to resolve the imaging volume. However, there are applications where the x-ray excitation may be limited by geometry, where increased temporal resolution is desired, or where a lower dose is mandatory. This paper extends the utility of XLT to meet these requirements by incorporating a photon propagation model into the reconstruction algorithm in an x-ray limited-angle (LA) geometry. This enables such applications as image-guided surgery, where the ability to resolve lesions at depths of several centimeters can be the key to successful resection. The hybrid x-ray/diffuse optical model is first formulated and then demonstrated in a breast-sized phantom, simulating a breast lumpectomy geometry. Both numerical and experimental phantoms are tested, with lesion-simulating objects of various sizes and depths. Results show localization accuracy with median error of 2.2 mm, or 4% of object depth, for small 2-14 mm diameter lesions positioned from 1 to 4.5 cm in depth. This compares favorably with fluorescence optical imaging, which is not able to resolve such small objects at this depth. The recovered lesion size has lower size bias in the x-ray excitation direction than the optical direction, which is expected due to the increased optical scatter. However, the technique is shown to be quite invariant in recovered size with respect to depth, as the standard deviation is less than 2.5 mm. Sensitivity is a function of dose; radiological doses are found to provide sufficient recovery for µg ml(-1) concentrations, while therapy dosages provide recovery for ng ml(-1) concentrations. Experimental phantom results agree closely with the numerical results, with positional errors recovered within 8.6% of the effective depth for a 5 mm object, and within 5.2% of the depth for a 10 mm object. Object-size median error is within 2.3% and 2% for the 5 and 10 mm objects, respectively. For shallow-to-medium depth applications where optical and radio-emission imaging modalities are not ideal, such as in intra-operative procedures, LAXLT may be a useful tool to detect molecular signatures of disease.
authors: Department of Radiation Oncology, School of Medicine, Stanford University, Stanford, CA 94305, USA. colincarpenter@stanford.edu
authors: C M
authors: CM
authors: Carpenter
authors: G
authors: G
authors: Pratx
authors: C
authors: C
authors: Sun
authors: L
authors: L
authors: Xing
references: J Natl Compr Canc Netw. 2009 Feb;7(2):215-25
references: 19200419
references: Phys Med Biol. 2008 Aug 21;53(16):4431-42
references: 18670053
references: Nanoscale Res Lett. 2011 Dec;6(1):24
references: 27502647
references: Med Phys. 1993 Mar-Apr;20(2 Pt 1):299-309
references: 8497214
references: J Opt Soc Am A Opt Image Sci Vis. 1995 Nov;12(11):2532-9
references: 7494154
references: J Urol. 2007 Dec;178(6):2694-700
references: 17945279
references: Phys Med Biol. 1990 Sep;35(9):1317-34
references: 2236211
references: Med Phys. 2001 Jun;28(6):868-93
references: 11439485
references: Opt Lett. 2010 Oct 15;35(20):3345-7
references: 20967061
references: Med Phys. 1995 Nov;22(11 Pt 1):1779-92
references: 8587533
references: Ann Surg Oncol. 2001 Oct;8(9):693-704
references: 11597009
references: J Nanosci Nanotechnol. 2008 Mar;8(3):1019-51
references: 18468106
references: Surg Oncol. 1993;2(3):137-43
references: 8252203
references: Cancer Res. 2003 May 1;63(9):1999-2004
references: 12727808
references: Opt Lett. 1995 Mar 1;20(5):426-8
references: 19859209
references: Appl Opt. 1998 Aug 1;37(22):5337-43
references: 18286015
references: Appl Opt. 2007 Apr 1;46(10):1669-78
references: 17356609
references: J Cancer Res Ther. 2007 Oct-Dec;3(4):231-5
references: 18270399
references: Arch Intern Med. 2009 Jun 8;169(11):1069-71
references: 19506177
references: Cancer Res. 2004 Nov 1;64(21):8009-14
references: 15520209
references: Med Phys. 2010 Aug;37(8):4011-8
references: 20879562
references: IEEE Trans Med Imaging. 2010 Dec;29(12):1992-9
references: 20615807
references: Phys Med Biol. 1996 Feb;41(2):297-307
references: 8746111
references: Ann Surg. 1968 Jun;167(6):820-8
references: 5690034
references: J Neurosurg. 2011 Mar;114(3):595-603
references: 20380535
references: J Nucl Med. 1990 Oct;31(10):1688-92
references: 2213194
references: Nature. 2008 Apr 3;452(7187):580-9
references: 18385732
references: Breast Cancer Res. 2005;7(3):110-2
references: 15987440
references: Cancer Res. 2001 Mar 1;61(5):1781-5
references: 11280722
references: J Neurosurg. 2000 Dec;93(6):1003-13
references: 11117842
references: Am J Surg. 1999 Oct;178(4):341-3
references: 10587196
references: Phys Med Biol. 1999 Jul;44(7):1767-89
references: 10442712
references: Neurosurgery. 2008 Mar;62(3):564-76; discussion 564-76
references: 18425006
references: Ann Surg Oncol. 2006 Dec;13(12):1671-81
references: 17009138
references: J Clin Oncol. 1999 Jan;17(1):101-9
references: 10458223